{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T15:58:18Z","timestamp":1772035098050,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1016\/j.clinthera.2010.03.003","type":"journal-article","created":{"date-parts":[[2010,4,18]],"date-time":"2010-04-18T10:57:52Z","timestamp":1271588272000},"page":"472-491","source":"Crossref","is-referenced-by-count":41,"title":["Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: A randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder"],"prefix":"10.1016","volume":"32","author":[{"given":"Jeffrey J.","family":"Miceli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas G.","family":"Tensfeldt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Shiovitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J.","family":"Anziano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cedric","family":"O'Gorman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel H.","family":"Harrigan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2010.03.003_bib1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2165\/00023210-200216040-00002","article-title":"Pharmacological treatment of psychotic agitation","volume":"16","author":"Currier","year":"2002","journal-title":"CNS Drugs"},{"key":"10.1016\/j.clinthera.2010.03.003_bib2","doi-asserted-by":"crossref","first-page":"494","DOI":"10.2165\/00003088-199528060-00007","article-title":"Emergency treatment of psychotic symptoms. Pharmacokinetic considerations for antipsychotic drugs","volume":"28","author":"Milton","year":"1995","journal-title":"Clin Pharmacokinet."},{"key":"10.1016\/j.clinthera.2010.03.003_bib3","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00004850-199705000-00009","article-title":"Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting","volume":"12","author":"Foster","year":"1997","journal-title":"Int Clin Psychopharmacol."},{"key":"10.1016\/j.clinthera.2010.03.003_bib4","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1192\/bjp.167.4.480","article-title":"Antipsychotic drug-induced dysphoria","volume":"167","author":"King","year":"1995","journal-title":"Br J Psychiatry."},{"key":"10.1016\/j.clinthera.2010.03.003_bib5","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/1099-1077(200010)15:7<521::AID-HUP235>3.0.CO;2-V","article-title":"A pilot study of intramuscular ziprasidone in the short-term treatment of patients with acute exacerbation of schizophrenia","volume":"15","author":"Brook","year":"2000","journal-title":"Hum Psychopharmacol."},{"key":"10.1016\/j.clinthera.2010.03.003_bib6","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s002130000658","article-title":"Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: A double-blind, randomized trial","volume":"155","author":"Daniel","year":"2001","journal-title":"Psychopharmacology (Berl)."},{"key":"10.1016\/j.clinthera.2010.03.003_bib7","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4088\/JCP.v62n0104","article-title":"Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients [published correction appears in J Clin Psychiatry. 2001;62:209]","volume":"62","author":"Lesem","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2010.03.003_bib8","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s00213-004-2082-5","article-title":"Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: Comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study","volume":"178","author":"Brook","year":"2005","journal-title":"Psychopharmacology (Berl)."},{"issue":"Suppl 3","key":"10.1016\/j.clinthera.2010.03.003_bib9","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0924-977X(02)80423-0","article-title":"Poster Session. Safety and tolerability of IM ziprasidone: Review of clinical trial data","volume":"12","author":"Zimbroff","year":"2002","journal-title":"Eur Neuropsychopharmacol."},{"key":"10.1016\/j.clinthera.2010.03.003_bib10","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/PR0.10.3.799-812","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol Rep."},{"key":"10.1016\/j.clinthera.2010.03.003_bib11","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1176\/appi.ajp.158.11.1774","article-title":"Antipsychotic drugs: Prolonged QTc interval, torsades de pointes, and sudden death","volume":"158","author":"Glassman","year":"2001","journal-title":"Am J Psychiatry."},{"key":"10.1016\/j.clinthera.2010.03.003_bib12","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2165\/00023210-200317060-00004","article-title":"Ziprasidone in the management of schizophrenia: The QT interval issue in context","volume":"17","author":"Taylor","year":"2003","journal-title":"CNS Drugs."},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2010.03.003_bib13","first-page":"1","article-title":"The QT interval","volume":"43","author":"Bednar","year":"2001","journal-title":"Prog Cardiovasc Dis."},{"key":"10.1016\/j.clinthera.2010.03.003_bib14","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jacc.2005.10.024","article-title":"QTc prolongation and sudden cardiac death: The association is in the detail","volume":"47","author":"Moss","year":"2006","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.clinthera.2010.03.003_bib15","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jacc.2005.08.067","article-title":"Prolonged QTc interval and risk of sudden cardiac death in a population of older adults","volume":"47","author":"Straus","year":"2006","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.clinthera.2010.03.003_bib16","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S0140-6736(99)02107-8","article-title":"Long QT syndromes and torsades de pointes","volume":"354","author":"Viskin","year":"1999","journal-title":"Lancet."},{"key":"10.1016\/j.clinthera.2010.03.003_bib17","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/01.jcp.0000104913.75206.62","article-title":"A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition","volume":"24","author":"Harrigan","year":"2004","journal-title":"J Clin Psychopharmacol."},{"key":"10.1016\/j.clinthera.2010.03.003_bib19","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2010.03.003_bib20","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/01.yic.0000166405.49473.70","article-title":"Antipsychotic drugs and QT prolongation","volume":"20","author":"St\u00f6llberger","year":"2005","journal-title":"Int Clin Psychopharmacol."},{"key":"10.1016\/j.clinthera.2010.03.003_bib21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/00004850-200401000-00002","article-title":"The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy","volume":"19","author":"Daniel","year":"2004","journal-title":"Int Clin Psychopharmacol."},{"key":"10.1016\/j.clinthera.2010.03.003_bib23","series-title":"Geodon [prescribing information]","year":"2008"},{"key":"10.1016\/j.clinthera.2010.03.003_bib24","series-title":"Haldol [prescribing information]","year":"2001"},{"key":"10.1016\/j.clinthera.2010.03.003_bib25","series-title":"Statistics","author":"Freedman","year":"2007"},{"key":"10.1016\/j.clinthera.2010.03.003_bib27","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.2165\/00003495-200262110-00006","article-title":"Antipsychotic-related QTc prolongation, torsades de pointes and sudden death","volume":"62","author":"Haddad","year":"2002","journal-title":"Drugs."},{"key":"10.1016\/j.clinthera.2010.03.003_bib28","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00406-008-0829-4","article-title":"The QTc interval and its dispersion in patients receiving two atypical antipsychotics","volume":"259","author":"Correll","year":"2009","journal-title":"Eur Arch Psychiatry Clin Neurosci."},{"key":"10.1016\/j.clinthera.2010.03.003_bib29","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4088\/JCP.v69n0115","article-title":"The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC): Design and baseline subject characteristics","volume":"69","author":"Strom","year":"2008","journal-title":"J Clin Psychiatry."},{"key":"10.1016\/j.clinthera.2010.03.003_bib30","doi-asserted-by":"crossref","first-page":"933","DOI":"10.4088\/JCP.v61n1208","article-title":"Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis","volume":"61","author":"Brook","year":"2000","journal-title":"J Clin Psychiatry."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291810000949?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291810000949?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,11]],"date-time":"2018-12-11T15:24:16Z","timestamp":1544541856000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291810000949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S0149291810000949"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2010.03.003","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}